Ellen Elizabeth Paxinos

8071284, Dec 6, 2011

Jun 6, 2006

11/916632

Soumi Gupta - San Francisco CA, US
Signe Fransen - San Francisco CA, US
Ellen Paxinos - San Jose CA, US
Neil T. Parkin - Belmont CA, US

Monogram Biosciences, Inc. - South San Francisco CA

C12Q 1/70

435 5, 435 2, 435 71

This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.

8637252, Jan 28, 2014

Nov 15, 2011

13/296370

Soumi Gupta - San Francisco CA, US
Signe Fransen - San Francisco CA, US
Ellen Paxinos - San Jose CA, US
Neil T. Parkin - Belmont CA, US

Monogram Biosciences, Inc. - South San Francisco CA

C12Q 1/68
C12Q 1/70
A61K 49/00

435 612, 435 5, 435 61, 435 618, 424 92

This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.

20040106106, Jun 3, 2004

Jul 1, 2003

10/612600

Neil Parkin - Belmont CA, US
Ellen Paxinos - San Jose CA, US
Colombe Chappey - San Francisco CA, US
Mary Wrin - Fremont CA, US
Andrea Gamarnik - Chandler AZ, US
Christos Petropoulos - Half Moon Bay CA, US

C12Q001/70
C07H021/02

435/005000, 536/023720

The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.

20090215028, Aug 27, 2009

Feb 16, 2006

11/884668

Ellen Paxinos - San Jose CA, US
Signe Fransen - San Francisco CA, US
Christos J. Petropoulos - Half Moon Bay CA, US

C12Q 1/70
C12N 15/63
C12N 5/00
C12N 5/08
C12N 5/10
C07H 21/04

435 5, 4353201, 435325, 435366, 435369, 536 231

This invention relates, in part, to methods and compositions for determining the susceptibility of an HIV to an anti-HIV drug or the replication capacity of an HIV. In certain embodiments, the methods comprise culturing a host cell in the presence of the anti-HIV drug, measuring the activity of the indicator gene in the host cell; and comparing the activity of the indicator gene as measured with a reference activity of the indicator gene. In certain embodiments, the difference between the measured activity of the indicator gene relative to the reference activity correlates with the susceptibility of the HIV to the anti-HIV drug, thereby determining the susceptibility of the HIV to the anti-HIV drug. In certain embodiments, the difference between the measured activity of the indicator gene relative to the reference activity indicates the replication capacity of the HFV, thereby determining the replication capacity of the HIV. In certain embodiments, the host cell comprises a patient-derived segment and an indicator gene. In certain embodiments, the patient-derived segment comprises a nucleic acid sequence that encodes integrase or RNAse H.